Daniel M. Geynisman, MD
- Request Appointment
- Clinical Locations
- Education, Training & Credentials
- Patient Stories
- Research Profile
Fox Chase Cancer Center
333 Cottman Avenue
Philadelphia, PA 19111
Chemotherapy, targeted therapy, immunotherapy, hormone therapy, clinical trials for genitourinary malignancies
I am a medical oncologist specializing in genitourinary cancers. I became a physician and an oncologist for many reasons including the ability to sometimes cure life-threatening illness, having the opportunity to care for ill patients, and being a part of a rapidly evolving and improving field. But perhaps the most important reason for entering oncology for me was the chance to build deep relationships with patients and their families at a time when they are the most vulnerable and in need, to be their advocate and resource, to guide them through a grueling time and hope with them for the best.
I believe that every cancer patient deserves the utmost compassionate, individualized, expert and prompt care. I came to Fox Chase after completing my fellowship at the University of Chicago because here I can offer just that. By working together with each patient, their family and a team of my expert colleagues, we can harness the most recent advances in oncology for each patient.
In my clinical practice I focus on the care of patients with prostate, kidney, bladder, penile, adrenal and testicular cancer and I am proud to be part of a large multidisciplinary team of distinguished clinicians and researchers at Fox Chase. Over the last decade, the number of treatment options for patients with advanced cancers has greatly expanded and at Fox Chase we can offer both the latest standard-of-care as well as new experimental approaches. My particular research interest is in health outcomes as well as clinical trials development for genitourinary cancers.
A cancer diagnosis is one of the most difficult times in a person’s life; my primary goal is to bring together all the resources of a cutting-edge cancer center to the patient in a compassionate and individualized manner.
- Fellow, Maclean Center for Clinical Medical Ethics, University of Chicago
- Fellow and Chief Fellow, Hematology and Medical Oncology, University of Chicago Medical Center
- Intern, Resident and Chief Resident, University of Pittsburgh Medical Center
- MD, University of Pittsburgh, Pittsburgh, PA, 2006
- American Board of Internal Medicine, Medical Oncology, 2013
- American Board of Internal Medicine, 2009
- American Society of Clinical Oncology
Honors & Awards
- ASCO/AACR Methods in Clinical Research Workshop Selected Participant, Vail, CO, 2014
- Illinois Medical Oncology Society Fellows Award, Chicago, Illinois, 2012
- Senior Presentation Award, University of Pittsburgh School of Medicine Department of Medicine, 2009
- Lucien J. Rubenstein Memorial Award, American Brain Tumor Association, 2003
- Morris H. and Gertrude M. Harris Foundation Scholarship, University of Pittsburgh School of Medicine, Pittsburgh, PA, 2002–2006
Debbie Getz is a fighter, there’s no doubting that. After beating inflammatory breast cancer in 1998, she continued diligently with follow-up oncology appointments. “Whenever something questionable showed up on an MRI or CAT Scan, I looked into it immediately,” Debbie recalls.
In March 2014, she experienced pain in her right side. “I thought it was a gall bladder attack,” admits Debbie, who quickly scheduled an appointment with her primary doctor, who sent her for imaging tests.
When he thinks back on October 28, 2013, Jim Tetzlaff realizes it would have been easy to ignore what happened and not give it another thought. “I’m a man – we have a tendency to ignore things that have to do with our health,” says Jim, who was 75 at the time. On that day, after one of his grandson’s football games, Jim went to the bathroom and saw blood in his urine. “It was upsetting, but I didn’t have any other symptoms so I thought it had to be a fluke,” recalls the former medical equipment salesman.
Drug development for genitourinary malignancies; Health outcomes/services research; Medical ethics
Geynisman DM, Ross EA, Plimack ER. Osteoclast Inhibitors in Advanced Prostate Cancer: Does the Benefit Extend Beyond Skeletal-Related Events? Eur Urol. 2015 Oct;68(4):578-80. doi: 10.1016/j.eururo.2015.06.009. Epub 2015 Jun 23. PubMed
Seeger-Nukpezah T, Geynisman DM, Nikonova AS, Benzing T, Golemis EA. The hallmarks of cancer: relevance to the pathogenesis of polycystic kidney disease. Nat Rev Nephrol. 2015 Sep;11(9):515-34. doi: 10.1038/nrneph.2015.46. Epub 2015 Apr 14. Review. PubMed
Geynisman DM. Anti-programmed Cell Death Protein 1 (PD-1) Antibody Nivolumab Leads to a Dramatic and Rapid Response in Papillary Renal Cell Carcinoma with Sarcomatoid and Rhabdoid Features. Eur Urol. 2015 Jul 17. pii: S0302-2838(15)00612-0. doi: 10.1016/j.eururo.2015.07.008. [Epub ahead of print] PubMed
Shih YC, Smieliauskas F, Geynisman DM, Kelly RJ, Smith TJ. Trends in the Cost and Use of Targeted Cancer Therapies for the Privately Insured Nonelderly: 2001 to 2011. J Clin Oncol. 2015 Jul 1;33(19):2190-6. doi: 10.1200/JCO.2014.58.2320. Epub 2015 May 18. PubMed PMID: 25987701; PubMed Central PMCID: PMC4477789. PubMed
Geynisman DM, Szmulewitz RZ, Plimack ER. Corticosteroids and prostate cancer: friend or foe? Eur Urol. 2015 May;67(5):874-5. doi: 10.1016/j.eururo.2014.08.008. Epub 2014 Aug 20. PubMed
Geynisman DM, Hu JC, Liu L, Tina Shih YC. Treatment patterns and costs for metastatic renal cell carcinoma patients with private insurance in the United States. Clin Genitourin Cancer. 2015 Apr;13(2):e93-100. doi: 10.1016/j.clgc.2014.08.013. Epub 2014 Sep 28. PubMed
Barth P, Dulaimi Al-Saleem E, Edwards KW, Millis SZ, Wong YN, Geynisman DM. Metastatic Extramammary Paget's Disease of Scrotum Responds Completely to Single Agent Trastuzumab in a Hemodialysis Patient: Case Report, Molecular Profiling and Brief Review of the Literature. Case Rep Oncol Med. 2015;2015:895151. doi: 10.1155/2015/895151. Epub 2015 Jan 27. PubMed PMID: 25692060; PubMed Central PMCID: PMC4322830. PubMed
Godwin JL, Zibelman M, Plimack ER, Geynisman DM. Immune checkpoint blockade as a novel immunotherapeutic strategy for renal cell carcinoma: a review of clinical trials. Discov Med. 2014 Dec;18(101):341-50. PubMed
Smieliauskas F, Chien CR, Shen C, Geynisman DM, Shih YC. Cost-effectiveness analyses of targeted oral anti-cancer drugs: a systematic review. Pharmacoeconomics. 2014 Jul;32(7):651-80. doi: 10.1007/s40273-014-0160-z. Review. PubMed
Shen C, Chien CR, Geynisman DM, Smieliauskas F, Shih YC. A review of economic impact of targeted oral anticancer medications. Expert Rev Pharmacoecon Outcomes Res. 2014 Feb;14(1):45-69. doi: 10.1586/14737167.2014.868310. Epub 2013 Dec 30. Review. PubMed
Geynisman DM, Chien CR, Smieliauskas F, Shen C, Shih YC. Economic evaluation of therapeutic cancer vaccines and immunotherapy: a systematic review. Hum Vaccin Immunother. 2014;10(11):3415-24. doi: 10.4161/hv.29407. PubMed
Geynisman DM. Doctor, where art thou? J Clin Oncol. 2013 Apr 20;31(12):1606-8. doi: 10.1200/JCO.2012.48.2059. Epub 2013 Mar 11. PubMed
Geynisman DM, Wickersham KE. Adherence to targeted oral anticancer medications. Discov Med. 2013 Apr;15(83):231-41. Review. PubMed
Geynisman DM, Zha Y, Kunnavakkam R, Aklilu M, Catenacci DV, Polite BN, Rosenbaum C, Namakydoust A, Karrison T, Gajewski TF, Kindler HL. A randomized pilot phase I study of modified carcinoembryonic antigen (CEA) peptide (CAP1-6D)/montanide/GM-CSF-vaccine in patients with pancreatic adenocarcinoma. J Immunother Cancer. 2013 Jun 27;1:8. doi: 10.1186/2051-1426-1-8. eCollection 2013. PubMed PMID: 24829746; PubMed Central PMCID: PMC4019890. PubMed
Geynisman DM, Szmulewitz RZ, Stadler WM. A trial postmortem: challenges in conducting a randomized, double-blind, phase 2 study in men with castration-resistant prostate cancer. Eur Urol. 2012 Nov;62(5):864-6. doi: 10.1016/j.eururo.2012.08.030. Epub 2012 Aug 25. PubMed